Gilead says Veklury should work against COVID-19 variantsGilead Sciences says its antiviral Veklury should be effective against the new, more contagious COVID-19 variants discovered in Share XGilead says Veklury should work against COVID-19 variantshttps://pharmaphorum.com/news/gilead-says-veklury-should-work-against-covid-19-variants/
Gilead Q3 revenue rise bolstered by $873m Veklury salesGilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment Share XGilead Q3 revenue rise bolstered by $873m Veklury saleshttps://pharmaphorum.com/news/gilead-q3-revenue-rise-bolstered-by-873m-veklury-sales/
BioSig abandons COVID-19 drug trial on safety concernsUS biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury Share XBioSig abandons COVID-19 drug trial on safety concernshttps://pharmaphorum.com/news/biosig-abandons-covid-19-drug-trial-on-safety-concerns/
Gilead’s remdesivir finally gets US approvalGilead’s Veklury (remdesivir) has become the first COVID-19 drug approved in the US following a nod from the Share XGilead’s remdesivir finally gets US approvalhttps://pharmaphorum.com/news/gileads-remdesivir-finally-gets-us-approval/
